DelveInsight’s “Acute Respiratory Distress Syndrome (ARDS) Pipeline Insight” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Acute Respiratory Distress Syndrome pipeline landscapes. It comprises Acute Respiratory Distress Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Acute Respiratory Distress Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Acute Respiratory Distress Syndrome pipeline products.     

 

Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report  

• Major companies such as Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others are developing potential drug candidates to improve the Acute Respiratory Distress Syndrome treatment scenario. 
• In February 2021, Athersys announced that it had entered into a cooperation agreement with HEALIOS. The cooperation agreement is intended to reaffirm the mutual commitment to the collaborative development of MultiStem in Japan.
• In March 2021, Partner Therapeutics announced a licensing and collaboration agreement with SIRS Therapeutics and F4 Pharma to support the development of FX-06. This synthetic peptide has a broad spectrum of potential indications.
• In June 2020, NeuroRx, in partnership with Relief Therapeutics, announced that the US FDA awarded Fast Track designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19.
• In December 2020, The Food and Drug Administration (FDA) granted Fast Track designation to remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19).
• In November 2020, Novartis announced that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L to treat acute respiratory distress syndrome.
• In September 2020, Dimerix was awarded USD 1 million from the Australian Government’s BTB program to support the inclusion of DMX-200 in the REMAP-CAP global study.
• In September 2020, Athersys announced that MultiStem cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA for the acute respiratory distress syndrome (ARDS) program. In May 2019, US FDA granted Fast Track designation to MultiStem cell therapy for ARDS.
• In June 2020, Quartesian announced a new partnership with Amyndas Pharmaceuticals for their Phase II clinical study evaluating the efficacy of AMY-101 in COVID-19 patients with acute respiratory distress syndrome (ARDS).

 

Get an overview of pipeline landscape @ ARDS Clinical Trials Analysis 

 

Scope of ARDS Pipeline Drug Insight    

• Coverage: Global 
• Major Players: 120+ Key Players
• Prominent Players: Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and many others.   
• Key Drugs Profiles: 120+ Products
• Phases:  

Acute Respiratory Distress Syndrome Therapies Late-stage (Phase III)  

Acute Respiratory Distress Syndrome Therapies Mid-stage (Phase II)

Acute Respiratory Distress Syndrome Therapies Early-stage (Phase I) 

Acute Respiratory Distress Syndrome Preclinical stage and Discovery candidates     

Discontinued and Inactive candidates  

• Mechanism of Action:

Complement C5 inhibitors

Angiotensin type 1 receptor antagonists

Myristoylated alanine-rich C kinase substrate inhibitors

Neurokinin 1 receptor antagonists

• Molecule Types:   

Peptides

Monoclonal antibodies

Stem cell therapies

Immunoproteins

Proteins

• Route of Administration:

Subcutaneous

Intramuscular

Intravenous

Oral

• Product Types:

Monotherapy

Combination

Mono/Combination 

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight

 

Key Questions regarding Current Acute Respiratory Distress Syndrome Treatment Landscape and Emerging Therapies Answered in the Pipeline Report  

• What are the current options for Acute Respiratory Distress Syndrome treatment?
• How many companies are developing therapies to treat Acute Respiratory Distress Syndrome? 
• How many ARDS emerging therapies in the early-stage, mid-stage, and late development stages to treat Acute Respiratory Distress Syndrome? 
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Acute Respiratory Distress Syndrome market? 
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies to treat Acute Respiratory Distress Syndrome?  
• What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing ARDS therapies? 
• What critical designations have been granted for the emerging therapies for Acute Respiratory Distress Syndrome? 
• How many patents are granted and pending for the emerging therapies to treat Acute Respiratory Distress Syndrome?   

 

Table of Contents 

1	Acute Respiratory Distress Syndrome Report Introduction
2	Acute Respiratory Distress Syndrome Executive Summary
3	Acute Respiratory Distress Syndrome Overview
4	ARDS Pipeline Therapeutics
5	Acute Respiratory Distress Syndrome Therapeutic Assessment
6	Acute Respiratory Distress Syndrome – DelveInsight’s Analytical Perspective In-depth Commercial Assessment
7	ARDS Late Stage Products (Phase III)
7.1	VERU-111: Veru
8	Acute Respiratory Distress Syndrome Mid Stage Products (Phase II/III)
8.1	FP-025: Foresee Pharmaceuticals
9	Acute Respiratory Distress Syndrome Early Stage Products (Phase I/II)
9.1	BX-U001: Bayx
10	Acute Respiratory Distress Syndrome Preclinical and Discovery Stage Products
11	ARDS Inactive Products
12	Acute Respiratory Distress Syndrome Key Companies
13	Acute Respiratory Distress Syndrome Key Products
14	ARDS Unmet Needs
15	Acute Respiratory Distress Syndrome Market Drivers and Barriers
16	Acute Respiratory Distress Syndrome Future Perspectives and Conclusion
17	Acute Respiratory Distress Syndrome Analyst Views
18	Appendix
19	About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-pipeline-insight